We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 03, 2021

Nivolumab Plus Ipilimumab for Stage IV Squamous Cell Lung Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
JAMA Oncol 2021 Jul 15;[EPub Ahead of Print], SN Gettinger, MW Redman, L Bazhenova, FR Hirsch, PC Mack, LH Schwartz, JD Bradley, TE Stinchcombe, NB Leighl, SS Ramalingam, SS Tavernier, H Yu, JM Unger, K Minichiello, L Highleyman, VA Papadimitrakopoulou, K Kelly, DR Gandara, RS Herbst

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading